Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes

References

• O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):111–15.
   Google Scholar
• Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23(3):415–24.
   PubMedGoogle Scholar
• Kontzias A, Kotlyar A, Laurence A, Changelian P, O’Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464–70.
   PubMedGoogle Scholar
• O’Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109 Suppl:S121–31.
   PubMed Web of Science ®Google Scholar
• Yarilina A, Xu K, Chan C, Ivashkiv LB. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012;64(12):3856–66.
   PubMedGoogle Scholar
• Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10(1):R14.
   PubMed Web of Science ®Google Scholar
• Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468–84.
   PubMedGoogle Scholar
• Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150–8.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012;367(6):495–507.
   PubMedGoogle Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19.
   PubMedGoogle Scholar
• Endo W, Arito M, Sato T, Kurokawa MS, Omoteyama K, Iizuka N, et al. Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes. Mod Rheumatol. 2013. doi:10.3109/14397595.2013.864225.
   Google Scholar
• Ogasawara N, Goto H, Watanabe T. Isozymes of rat AMP deaminase. Biochim Biophys Acta. 1975;403(2):530–7.
   PubMedGoogle Scholar
• Ogasawara N, Goto H, Yamada Y, Watanabe T. Distribution of AMP-deaminase isozymes in rat tissues. Eur J Biochem. 1978;87(2): 297–304.
   PubMedGoogle Scholar
• Ogasawara N, Goto H, Yamada Y, Watanabe T, Asano T. AMP deaminase isozymes in human tissues. Biochim Biophys Acta. 1982;714(2):298–306.
   PubMedGoogle Scholar
• Ogasawara N, Goto H, Yamada Y, Watanabe T. Distribution of AMP deaminase isozymes in various human blood cells. Int J Biochem. 1984;16(3):269–73.
   PubMedGoogle Scholar
• Sabina RL, Morisaki T, Clarke P, Eddy R, Shows TB, Morton CC, Holmes EW. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem. 1990;265(16):9423–33.
   PubMedGoogle Scholar
• Bausch-Jurken MT, Mahnke-Zizelman DK, Morisaki T, Sabina RL. Molecular cloning of AMP deaminase isoform L. Sequence and bacterial expression of human AMPD2 cDNA. J Biol Chem. 1992;267(31):22407–13.
   PubMedGoogle Scholar
• Mahnke-Zizelman DK, Sabina RL. Cloning of human AMP deaminase isoform E cDNAs. Evidence for a third AMPD gene exhibiting alternatively spliced 5’-exons. J Biol Chem. 1992;267(29):20866–77.
   PubMedGoogle Scholar
• Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update. Pharmacol Rev. 2011;63(1):1–34.
   PubMedGoogle Scholar
• Mediero A, Cronstein BN. Adenosine and Bone Metabolism. Trends Endocrinol Metab. 2013;24(6):290–300.
   PubMedGoogle Scholar
• Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148(7):2201–6.
   PubMedGoogle Scholar
• Bitto A, Polito F, Irrera N, D’Ascola A, Avenoso A, Nastasi G, et al.Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A(2A) receptor. Arthritis Rheum. 2011;63(11):3364–71.
   PubMedGoogle Scholar
• Petrov R, MacDonald MH, Tesch AM, Benton HP. Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage. 2005;13(3):250–7.
   PubMedGoogle Scholar
• Mazzon E, Esposito E, Impellizzeri D, DI Paola R, Melani A, Bramanti P, et al. CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis. J Rheumatol. 2011;38(10):2119–29.
   PubMedGoogle Scholar
• Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J. 1992;282(Pt 1):197–202.
   PubMedGoogle Scholar
• Baggott JE, Morgan SL, Ha TS, Alarcon GS, Koopman WJ, Krumdieck CL. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol. 1993;11 (Suppl 8):S101–5.
   PubMedGoogle Scholar
• Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991;88(6):2441–5.
   PubMedGoogle Scholar
• Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92(6):2675–82.
   PubMedGoogle Scholar
• Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156(5):1937–41.
   PubMedGoogle Scholar